The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments

Endocrine-based treatments are the normal standard-of-care in women with hormone receptor-positive/Human Epidermal growth factor Receptor 2-negative metastatic breast cancer. Despite the well-known efficacy of these drugs as first-line therapies, about 50% of women develop endocrine resistance and d...

Full description

Bibliographic Details
Main Authors: Daniele Presti, Erica Quaquarini
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
metastatic breast cancer
endocrine resistance
PI3K
CDK4/6 inhibitors
mTOR
Online Access:https://www.mdpi.com/2072-6694/11/9/1242

Similar Items

Similar Items